866-997-4948(US-Canada Toll Free)

Metastatic Ovarian Cancer - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Apr 2013

Category :

Ovarian Cancer

No. of Pages : 43 Pages

 

Global Markets Direct’s, \'Metastatic Ovarian Cancer - Pipeline Review, H2 2013\', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer. 

 

Metastatic Ovarian Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Metastatic Ovarian Cancer.
  • A review of the Metastatic Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Ovarian Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Ovarian Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Ovarian Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

 

Introduction

Global Markets Direct Report Coverage

Metastatic Ovarian Cancer Overview

Therapeutics Development

An Overview of Pipeline Products for Metastatic Ovarian Cancer

Metastatic Ovarian Cancer Therapeutics under Development by Companies

Late Stage Products

Comparative Analysis

Mid Clinical Stage Products

Comparative Analysis

Discovery and Pre-Clinical Stage Products

Comparative Analysis

Metastatic Ovarian Cancer Therapeutics – Products under Development by Companies

Companies Involved in Metastatic Ovarian Cancer Therapeutics Development

F. Hoffmann-La Roche Ltd.

Daiichi Sankyo Company, Ltd

Dainippon Sumitomo Pharma Co., Ltd.

Aphios Corporation

Cell Therapeutics, Inc.

Metastatic Ovarian Cancer – Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

tigatuzumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

brostallicin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

APH-0912 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

bevacizumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Tumor Adaptive Responses Program - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Tumor Microenvironment Program - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SM-276001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Metastatic Ovarian Cancer Therapeutics – Drug Profile Updates

Metastatic Ovarian Cancer Therapeutics – Discontinued Products

Metastatic Ovarian Cancer Therapeutics - Dormant Products

Metastatic Ovarian Cancer – Product Development Milestones

Featured News & Press Releases

Oct 02, 2012: Merrimack Pharma Presents Phase I Study Of MM-121 At European Society For Medical Oncology 2012

 

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Table

 

Number of Products Under Development for Metastatic Ovarian Cancer, H1 2013

Products under Development for Metastatic Ovarian Cancer – Comparative Analysis, H1 2013

Number of Products under Development by Companies, H1 2013

Comparative Analysis by Late Stage Development, H1 2013

Comparative Analysis by Mid Clinical Stage Development, H1 2013

Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013

Products under Development by Companies, H1 2013

F. Hoffmann-La Roche Ltd., H1 2013

Daiichi Sankyo Company, Ltd, H1 2013

Dainippon Sumitomo Pharma Co., Ltd., H1 2013

Aphios Corporation, H1 2013

Cell Therapeutics, Inc., H1 2013

Assessment by Monotherapy Products, H1 2013

Assessment by Stage and Route of Administration, H1 2013

Assessment by Stage and Molecule Type, H1 2013

Metastatic Ovarian Cancer Therapeutics – Drug Profile Updates

Metastatic Ovarian Cancer Therapeutics – Discontinued Products

Metastatic Ovarian Cancer Therapeutics – Dormant Products

List of Chart

 

Number of Products under Development for Metastatic Ovarian Cancer, H1 2013

Products under Development for Metastatic Ovarian Cancer – Comparative Analysis, H1 2013

Products under Development by Companies, H1 2013

Late Stage Products, H1 2013

Mid Clinical Stage Products, H1 2013

Discovery and Pre-Clinical Stage Products, H1 2013

Assessment by Monotherapy Products, H1 2013

Assessment by Route of Administration, H1 2013

Assessment by Stage and Route of Administration, H1 2013

Assessment by Molecule Type, H1 2013

Assessment by Stage and Molecule Type, H1 2013

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *